236 related articles for article (PubMed ID: 24447908)
21. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
[TBL] [Abstract][Full Text] [Related]
22. Determinants for successful marketing authorisation of orphan medicinal products in the EU.
Putzeist M; Heemstra HE; Garcia JL; Mantel-Teeuwisse AK; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2012 Apr; 17(7-8):352-8. PubMed ID: 22094244
[TBL] [Abstract][Full Text] [Related]
23. [European Agency for the Evaluation of Medicinal Products: five years experience].
Sauer F
Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
[TBL] [Abstract][Full Text] [Related]
24. Update of EMA's Guideline on the Environmental Risk Assessment (ERA) of Medicinal Products for Human Use.
Wess RA
Ther Innov Regul Sci; 2021 Mar; 55(2):309-323. PubMed ID: 32996106
[TBL] [Abstract][Full Text] [Related]
25. [How does a new medicine reach the patient?].
Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
[TBL] [Abstract][Full Text] [Related]
26. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
27. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
[TBL] [Abstract][Full Text] [Related]
28. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
29. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
30. The regulatory system in europe with special emphasis on allergen products.
Lorenz AR; Luttkopf D; Seitz R; Vieths S
Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
[TBL] [Abstract][Full Text] [Related]
31. The licensing of medicines in the UK.
Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
[TBL] [Abstract][Full Text] [Related]
32. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
Rubino A; Artime E
Expert Opin Drug Saf; 2017 Aug; 16(8):877-884. PubMed ID: 28548608
[TBL] [Abstract][Full Text] [Related]
33. The contribution of field efficacy studies to the evaluation of applications for veterinary vaccines evaluated through the European Union centralised authorisation procedure.
Mackay D; Jimenez CM; Ioannou F; Ilott M
Biologicals; 2021 Apr; 70():7-16. PubMed ID: 33840590
[TBL] [Abstract][Full Text] [Related]
34. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
35. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
Martinac AI; Tomić S; Simicić M
Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
[TBL] [Abstract][Full Text] [Related]
36. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
37. [Registration of new medicinal products in Europe].
Singer E
Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
[TBL] [Abstract][Full Text] [Related]
38. Experiences with the OECD 308 transformation test: a human pharmaceutical perspective.
Ericson JF; Smith RM; Roberts G; Hannah B; Hoeger B; Ryan J
Integr Environ Assess Manag; 2014 Jan; 10(1):114-24. PubMed ID: 23794155
[TBL] [Abstract][Full Text] [Related]
39. The regulatory framework of biosimilars in the European Union.
Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
[TBL] [Abstract][Full Text] [Related]
40. Orphan drugs assessment in the centralised procedure.
Nisticò G
Ann Ist Super Sanita; 2011; 47(1):98-9. PubMed ID: 21430347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
